The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ -- EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of peptides known as "Tregitopes" on antibody maturation during immune response.
Lymph nodes contain antibodies that undergo changes to their sequence as they adapt to their immune target, such as a flu virus. As this happens, the content of regulatory T cell (Treg) epitope sequences (also called Tregitopes) in the antibodies appears to decrease, which enables the B cells to expand and persist.
The study, " Regulatory T Cell Epitope Content in Human Antibodies Decreases During Maturation", was conducted by Andres Gutierrez, PhD and Annie De Groot, MD of EpiVax, using existing antibody sequence data. "This work provides important insights into how antibodies evolve over time, not just in terms of affinity, but in their ability to engage with the immune system." said Dr. Gutierrez.
The discovery of Tregitopes in 2008 marked a shift in awareness about the function of natural Tregs in human and animal immunity. Tregitopes may explain, in part, the tolerogenic impact of IV immunoglobulin therapy (IVIG). Tregitope-like peptides have since been found in other self-proteins.
A prior analysis of human antibody repertoires demonstrated that T cell epitopes decreased with increasing antibody maturation. However, that study didn't separate regulatory from effector T cell epitope dynamics. In this study, researchers examined antibody repertoires from four healthy human donors. They assessed three subsets of T cell epitopes: previously validated Tregitopes, potentially tolerated T cell epitopes and potential effector T cell epitopes.
Findings revealed that as antibodies mature and have higher affinity for their target antigen, Tregitope content systematically decreases, while potential effector T cell epitope content increases. This suggests that Tregitope depletion is a fundamental feature of antibody evolution. The observation was confirmed by testing some of the 'natural' and 'modified' Tregitope sequences in vitro.
"This mechanism is likely relevant to immunity from pathogens, to the development of autoantibodies during autoimmune disease, and for the selection of therapeutic antibody candidates", said Dr. De Groot. "We are pleased to contribute this finding to the literature on immune regulation and antibody design."
About EpiVax
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for therapeutics and vaccines. EpiVax collaborates with globally recognized partners to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
Korea Herald
3 days ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact
Korea Herald
3 days ago
- Korea Herald
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.
